Recor Medical Responds to the American Heart Association’s (AHA) Scientific Statement on Renal Denervation for the Treatment of Hypertension Palo Alto, CA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) greatly appreciate the American...

First Patients Treated in Recor Medical’s Global Paradise System US Post Approval Study (US GPS) for the Treatment of Uncontrolled Hypertension with Ultrasound Renal Denervation Palo Alto, CA, July 25, 2024 (GLOBE NEWSWIRE) -- Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced the first patients...

Recor Medical Champions Global Action on World Hypertension Day: Early Intervention and Continued Innovation Crucial in Tackling This Silent Killer Impacting Billions Worldwide Palo Alto, CA, May 17, 2024 (GLOBE NEWSWIRE) -- Hypertension, or high blood pressure, affects nearly half of all Americans and more than one billion people worldwide.  Hypertension is known as the...

Recor Medical Announces First Cases of Paradise Ultrasound Renal Denervation Therapy in the United Arab Emirates Palo Alto, CA, April 18, 2024 (GLOBE NEWSWIRE) -- Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), announce the first commercial...